𝔖 Bobbio Scriptorium
✦   LIBER   ✦

High versus low dose granisetron, a selective 5HT3antagonist, for the prevention of chemotherapy-induced nausea and vomiting

✍ Scribed by H. C. Falkson; C. I. Falkson; G. Falkson

Publisher
Springer US
Year
1990
Tongue
English
Weight
173 KB
Volume
8
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

✦ Synopsis

Fifty six patients, with histologically confirmed cancer, who received highly emetogenic chemotherapy, were entered on a randomized double blind, low versus high dose, study of granisetron, a 5HT3 receptor antagonist. A single dose of intravenous granisetron protected the majority of patients from nausea and vomiting, 160 micrograms/kg was more effective than 40 micrograms/kg with no more side effects. Additional doses of granisetron conferred added benefit to patients who experienced breakthrough symptoms. Granisetron at a dose range of 40-240 micrograms/kg over a 24 hour period was well tolerated with the only side effect being mild headache.

πŸ“œ SIMILAR VOLUMES

Ondasetron versus granisetron in the pre
Ondasetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial
✍ Vittorio Gebbia; Giuseppe Cannata; Antonio Testa; Giuseppina Gurto; Roberto Vale πŸ“‚ Article πŸ“… 1994 πŸ› John Wiley and Sons 🌐 English βš– 731 KB

Background. A single-institution, prospective, randomized open trial was performed to compare ondansetron and granisetron in the prevention of chemotherapyrelated nausea and vomiting. The effect of antemetic drugs was analyzed indipendently for patients treated with highly emetogenic chemotherapy (S

Improved prevention of moderately emetog
Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist : Results of a Phase III, single-dose trial versus dolasetron
✍ Peter Eisenberg; Jazmin Figueroa-Vadillo; Rosalio Zamora; Veena Charu; Julio Haj πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 174 KB

## Background: Palonosetron, a highly selective and potent 5-ht(3) receptor antagonist with a strong binding affinity and a long plasma elimination half-life (approximately 40 hours), has shown efficacy in phase ii trials in preventing chemotherapy-induced nausea and vomiting (cinv) resulting from

A phase I study of a new 5HT3-receptor a
A phase I study of a new 5HT3-receptor antagonist, BRL43694A, an agent for the prevention of chemotherapy-induced nausea and vomiting
✍ Geoffrey Falkson; Adriaan J. Zyl πŸ“‚ Article πŸ“… 1989 πŸ› Springer 🌐 English βš– 370 KB

In a phase I study of BRL43694A, a 5HT3-receptor antagonist, a single dose of 40 micrograms/kg was given to 24 patients. All patients received cytostatic treatment expected to cause nausea and vomiting. During the first 24 h, 12 patients were completely protected from nausea and vomiting, 4 experien

Establishing the dose of the oral NK1 an
Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting
✍ Sant P. Chawla; Steven M. Grunberg; Richard J. Gralla; Paul J. Hesketh; Cindy Ri πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 152 KB

## Abstract ## BACKGROUND The neurokinin‐1 antagonist aprepitant (EMENDβ„’; Merck Research Laboratories, West Point, PA) has been shown to reduce chemotherapy‐induced nausea and vomiting when it is given with a 5‐hydroxytryptamine‐3 receptor antagonist and dexamethasone. The current study sought to